Sai Life Sciences Ltd News

Pharma index surges 2%; Torrent, Mankind, Cipla, Aurobindo soar up to 5%

Pharma stocks: RPG Life, Thyrocare, Hester Biosciences, Rubicon Research, IOL Chemicals, Emcure and Suven Life from the BSE Healthcare index rallied between 4% and 8% on Monday.

Nifty Pharma index up 2%; Dr Reddy's, Ajanta, Ipca, Cipla surge up to 5%

In the past seven trading days, the Nifty Pharma index outperformed the market by soaring 5.4 per cent, as compared to 0.1 per cent decline in the Nifty 50.

Analysts project up to 17% upside in healthcare stocks trading at new highs

Apollo Hospitals, Aster DM Healthcare, Sai Life Sciences have rallied up to 27% thus far in FY27; technical analysts remain bullish on these stocks given the favourable chart set-up.

Sai Life, Laurus Labs hit new highs; stocks rally up to 40% in 6 months

Sai's management reiterated long-term guidance of 15-20 per cent revenue CAGR with 28-30 per cent steady state EBITDA margin over the next two to three years.

CDMO stocks in focus: Laurus Labs hits new high; Sai Life Sciences gains 2%

In the past one month, Laurus Labs and Sai Life shares have surged 18 per cent and 15 per cent, respectively. In comparison, the BSE Sensex has slipped 4.2 per cent.

Marico, Nestle, Laurus, Grasim and 15 others from Nifty 500 hit new highs

Vijaya Diagnostic Centre was quoting higher for the eight straight trading day, soaring 25 per cent during the period.

Laurus, Sai Life Sciences up 3% in weak market; what's driving CDMO stocks?

In the past one month, Laurus (up 14 per cent) and Sai Life (up 15 per cent) have outperformed the market by soaring up to 15 per cent

Nifty Pharma index soars 3%; Dr Reddy's, Piramal Pharma rally up to 9%

Glenmark Pharma, Cipla, Wockhardt, Mankind Pharma, Lupin, Zydus Life, Laurus, Ipca Labs, Divis Labs, Strides Pharma and Onesource were up in the range of 3% to 6%.

Jefferies names Sai Life Sciences top CRDMO pick, lists 10 reasons to buy

The brokerage noted that Sai Life remains relatively small compared with its addressable market, with FY25 sales of about $200 million, providing significant room for expansion

Sai Life hits record high in weak market; rebounds 5% from day's low

Supported by solid demand, disciplined execution, and capex programs progressing as planned, Sai Life management remains confident in sustaining positive growth momentum.

Sai Life soars 25% in 5 weeks, hits record high in weak market; here's why

ICRA expects Sai Life Sciences to maintain strong growth momentum over the medium term on the back of a healthy growth outlook for the industry, good product mix and deepening customer engagement.

Sai Life Sciences shares jump 8% as Q3 profit surges 86% YoY

Sai Life Sciences has invested ₹405 crore in capital expenditure so far, against its planned outlay of ₹700 crore for FY26